Conorfamide As2a: this amidated form is active on both ASIC channels and nicotinic acetylcholine receptors (nAChRs) (PubMed:31028742). Potentiates ASIC1a (EC(50)=10.9 uM) (PubMed:31028742). Inhibits desensitization of ASIC1a and to a lesser degree ASIC3 currents, resulting in a sustained opening of channels in the presence of low pH (PubMed:31028742). Inhibits with a slow reversibility human alpha-7/CHRNA7 nAChRs (IC(50)=689-3867 nM) and with a rapid reversibility human alpha-1-beta-1-delta-epsilon (CHRNA1-CHRNB1-CHRND-CHRNE) nAChRs (IC(50)=208 nM) (PubMed:31028742). Conorfamide As2b: this non-amidated form is only weakly active on both ASIC channels and nicotinic acetylcholine receptors (nAChRs) (PubMed:31028742). Shows a very weak inhibition of peak current of rat ASIC1a and ASIC3 (PubMed:31028742). No inhibition or very weak desensitization of both rat ASIC1a and ASIC3 are observed (PubMed:31028742). Reversibly inhibits both human alpha-7/CHRNA7 nAChRs (IC(50)=2971-7036 nM) and human alpha-1-beta-1-delta-epsilon (CHRNA1-CHRNB1-CHRND-CHRNE) nAChRs (IC(50)=707 nM) (PubMed:31028742). Expressed by the venom duct. Both amidated and non-amidated conorfamides As2 are found in the venom. Amidation is important since amidated peptide is more active. Conorfamide As2a. Conorfamide As2b. Belongs to the FARP (FMRFamide related peptide) family.